An Evidence-Based Review of OLZ/SAM for Treatment of Adults with Schizophrenia or Bipolar I Disorder [Corrigendum]

Abstract

Citrome L, Graham C, Simmons A, et al. Neuropsychiatr Dis Treat. 2021;17:2885–2904. The authors have advised there is an error in Figure 1C on page 2894. The key “OLZ/SAM” should read “Olanzapine + samidorphan 10 mg” and “Olanzapine” should read “Olanzapine + placebo”. Figure 1 legend, the text “Panel (C) In ALK3831-302, antipsychotic efficacy, as measured by the change from baseline in the PANSS total score at week 12 in the combined OLZ/SAM groups (OLZ/SAM 5/10 mg, 10/10 mg, and 20/10 mg) versus olanzapine was the primary endpoint; only the olanzapine + placebo and olanzapine + samidorphan 10-mg groups are presented here to allow cross-study comparisons” should read “Panel (C) In ALK3831-302, antipsychotic efficacy, as measured by the change from baseline in the PANSS total score at week 12, was the primary endpoint comparing the combined olanzapine + samidorphan groups versus the olanzapine + placebo group; to allow cross-study comparisons, only the olanzapine + samidorphan 10-mg and the olanzapine + placebo groups are presented here”. Read the original article

Keywords

• antipsychotic agents
• clinical efficacy
• olanzapine
• opioid antagonists
• safety
• weight gain